Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Click Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: https://www.clicktherapeuti...
Year Founded: 2012
Status: Private
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Jan 30, 2024
Finance
Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast
Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Mar 23, 2022
Management Tracks
Sandrock becomes CEO at Voyager
Plus Faga replaces Suria as Anaptys CEO and updates from Mozart, Longboard, Capsida, Phathom and more
BioCentury | Oct 23, 2021
Product Development
Oct. 22 Quick Takes: FDA approves Genentech’s ocular implant for wet AMD
$118M IPO values Xilio at $427M, plus Genentech, Merck, Sanofi and more
BioCentury | Dec 3, 2020
Finance
Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click
AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen
BioCentury | Sep 16, 2020
Deals
Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology
NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ)
BioCentury | Jan 3, 2020
Emerging Company Profile
Click: personalized digital therapeutics for cognitive, neurobehavioral disorders
Click harnesses user experience data to develop apps for neurobehavioral disorders
BioCentury | Nov 16, 2019
Product Development
Navigating IP strategies in the world of digital therapeutics
Digital therapeutics makers are looking to the tech industry for IP strategies
BioCentury | Nov 9, 2019
Company News
Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange
Items per page:
1 - 10 of 13